• Steady performance in a challenging environment: Amcor CEO Ron Delia
    Steady performance in a challenging environment: Amcor CEO Ron Delia
Close×

Profits at packaging giant Amcor are approaching US$1bn, with the company’s CEO Ron Delia signaling the company is looking at acquisition to drive further growth, as he described the year as “outstanding.”

 

Amcor’s full year revenue was up by 3.2 per cent to US$12.9bn, its EBITDA rose by six per cent to $US2.02bn, while its net profit jumped by 53 per cent or $US$327m, to US$930m.

Flexibles and rigids both grew, with flexibles up to US$10bn from US$9.75bn in 2020, and a ten per cent rise in EBIT, up to US$1.43bn, while rigids rose to US$2.82bn from US$2.72bn, with an EBIT that grew to US$299m from US$284m.

The company said its position in grocery staples, healthcare and medicine had given it a strong platform in Covid.

Ron Delia, CEO at Amcor said, “FY 2021 was an outstanding year for Amcor on multiple dimensions. The operating environment remains highly dynamic, but our teams stayed fully focused on the key business drivers within our control, remained agile as conditions changed, and demonstrated exceptional execution and consistency all year. Financial results exceeded our expectations.

“It was an exceptional year financially for Amcor, with record earnings, exceptional margin management, despite steep raw material cost increases, and supply constraints, and momentum building through the year. Organic sales growth was two per cent, and we exited the year in Q4 with sales higher than the prior year.”

Delia indicated that the company was back on the acquisition trail, and was looking at Asia in particular, but would not pay over the odds for a business.

Amcor is now listed on the New York stock exchange following its US$9bn takeover of Bemis two years ago, with integration now complete.

Food & Drink Business

Australia’s first social enterprise bakery, The Bread & Butter Project, has graduated its latest group of bakers, with its largest ever cohort marking the program’s 100th graduate.

The University of Sydney and Peking University have launched a Joint Centre for Food Security and Sustainable Agricultural Development, which will support research into improving the sustainability and security of food systems in Australia and China.

Sydney-based biotech company, All G, has secured regulatory approval in China to sell recombinant (made from microbes, not cows) lactoferrin. CEO Jan Pacas says All G is the first company in the world to receive the approval, and recombinant human lactoferrin is “next in line”.